Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Context Therapeutics Inc.
Report date February 15, 2022 · Filed February 17, 2022
Section 16 reporting ended · disclosed 2022-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2032-02-14 | Direct | 29,223 |
Reported balance
After 2022-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 29,223 · Balance 29,223 F1: The stock option vests in equal monthly installments with 1/13th vesting on the last day of the calendar month in which the grant occurs and 1/13th on the last day of each subsequent month until fully vested on February 28, 2023. Additionally, 29,225 previously granted but unvested restricted stock units were cancelled as of December 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments with 1/13th vesting on the last day of the calendar month in which the grant occurs and 1/13th on the last day of each subsequent month until fully vested on February 28, 2023. Additionally, 29,225 previously granted but unvested restricted stock units were cancelled as of December 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 16:56 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 29,223 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001842952-22-000016 · wf-form4_164513498176142.xml · derivative · entry 1 Dick Evan G. · CIK 0001862116 · Former Section 16 officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,223 Underlying: Common Stock · 0 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests in equal monthly installments with 1/13th vesting on the last day of the calendar month in which the grant occurs and 1/13th on the last day of each subsequent month until fully vested on February 28, 2023. Additionally, 29,225 previously granted but unvested restricted stock units were cancelled as of December 30, 2021. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:29 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries Seed Preferred Stock · Derivative | 26,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009608 · edgar.xml · derivative · entry 2 Dick Evan G. · CIK 0001862116 · SVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Fully vested. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 17:29 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 26,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-009608 · edgar.xml · nonDerivative · entry 1 Dick Evan G. · CIK 0001862116 · SVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F2 · balance_after: Includes 39,659 restricted stock units which fully vest on February 24, 2023. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:12 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionSeries Seed Preferred Stock · Derivative | 26,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000025 · wf-form4a_163977554088927.xml · derivative · entry 2 Dick Evan G. · CIK 0001862116 · SVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Fully vested. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| October 22, 2021 Filed Dec 17, 2021 16:12 UTC Amendment | Context Therapeutics Inc. CNTX · Entity 7406 | ConversionCommon Stock | 26,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842952-21-000025 · wf-form4a_163977554088927.xml · nonDerivative · entry 1 Dick Evan G. · CIK 0001862116 · SVP of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F2 · balance_after: Includes 33,397 restricted stock units which fully vest on January 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.